{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"14.260","floor":"13.060"},"ipodate":{"start":"2019-05-31 00:00:00","end":"2019-06-05 00:00:00"},"minimumcapital":"28807.40","subscribed":"11.77","marketcap":"813.66億","H_marketcap":"--","pe":"37.68","codesrate":"60.01","link":"https://staticpdf.iqdii.com/stockdata/notice/03692/2019/LTN20190531016_C.pdf","ipopricing":"14.260","resultdate":"2019-06-13 00:00:00","enddate":"2019-06-05 00:00:00","listeddate":"2019-06-14 00:00:00","issuenumber":"55128.00萬","issuenumberhK":"3859.00萬","issuenumberother":"51269.00萬","grayprice":"16.02","sponsors":"摩根士丹利亞洲有限公司,花旗環球金融亞洲有限公司","raisemoney":"764000.00萬","use":"1、所得款項凈額約45%或3,438百港元用于研發（包括我們現有及未來的國內及海 外藥物開發項目）、擴充我們的研發團隊及于研發技術的投資；\n2、約25%或1,910百港元用于生產體系，建設新生產線，升級現有生產設施并提 高其自動化水平；\n3、約20%或1,528百港元用于銷售及學術推廣，以配合新產品上市，尤其是四種 將自2019年至2020年上市的創新藥；\n4、余款約10%或764百港元將用于撥付我們的營運資金及其他一般企業用途。","shares":2000,"leadagent":"摩根士丹利亞洲有限公司,花旗環球金融亞洲有限公司,瑞士銀行香港分行,高盛(亞洲)有限責任公司,招商證券(香港)有限公司,中國國際金融香港證券有限公司,招銀國際融資有限公司","bookrunners":"摩根士丹利亞洲有限公司,花旗環球金融亞洲有限公司,瑞士銀行香港分行,高盛(亞洲)有限責任公司,招商證券(香港)有限公司,中國國際金融香港證券有限公司","coordinator":"摩根士丹利亞洲有限公司,花旗環球金融亞洲有限公司,瑞士銀行香港分行,高盛(亞洲)有限責任公司,招商證券(香港)有限公司","firstDayOpen":"16.30","IsEiio":0,"Interestdays":8,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根士丹利亞洲有限公司","code":"E03692","name":"翰森制藥","fullname":"翰森制藥集團有限公司"},"institutioninfo":{"principaloffice":"中國江蘇連云港經濟技術開發區東晉路9號","registrars":"卓佳證券登記有限公司","registrarstel":"(852)2980 1333","chairman":"鐘慧娟","secretary":"鐘勝利,李昕穎","telephone":"(860518)8309 6666","substantialshareholders":"Stellar Infinity(68.35%),Apex Medical(16.65%)","principalactivities":"公司為在中國規模最大、增長最快、臨床需求缺口巨大的部分治療領域均排名前列的少數幾家研發驅動型中國制藥公司之一。","website":"--"},"managerinfo":[{"managername":"鐘慧娟","post":"主席、首席執行官兼執行董事","rankno":1},{"managername":"呂愛鋒","post":"執行董事","rankno":2},{"managername":"孫遠","post":"執行董事","rankno":3}],"investorinfo":[{"institutionname":"GIC Private Limited","shareholding":"38,532,000.0","percentage":6.99,"ReleaseDate":"2019-12-14 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"},{"institutionname":"Boyu Capital Opportunities Master Fund","shareholding":"33,026,000.0","percentage":5.99,"ReleaseDate":"2019-12-14 00:00:00","relatedparty":"Boyu Capital Investment Management Co., Limited","subsidiary":["Boyu Capital Opportunities Master Fund"],"InverstorType":"基金"},{"institutionname":"Prime Capital Funds","shareholding":"22,018,000.0","percentage":3.99,"ReleaseDate":"2019-12-14 00:00:00","relatedparty":"涌金資產管理有限公司","subsidiary":["Prime Capital Funds","Dragon Billion China Master Fund"],"InverstorType":"基金"},{"institutionname":"Worldwide Healthcare Trust PLC","shareholding":"22,018,000.0","percentage":3.99,"ReleaseDate":"2019-12-14 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"}],"TotalShareholdingPercentage":34.36},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":507}